References
- + Text Zoom
  1. Escudier B, Szczylik C, Eisen T, et al; for the BAY 43-9006 TARGETs Clinical Trial Group. Randomized phase III trial of sorafenib (BA 43-9006)—an oral multi-kinase inhibitor—in patients with advanced RCC. Presentation: 41st ASCO Annual Meeting; May 13-17, 2005; Orlando, FL. http://www.asco.org.
  2. Escudier B, Eisen T, Stadler WM, et al, for the TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
  3. Bukowski RM, Eisen T, Szczylik C, et al, for the Sorafenib TARGET Clinical Trial Group. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. Presentation: 43rd ASCO Annual Meeting; June 1-5, 2007; Chicago, Ill.
  4. Grotzinger J. Molecular mechanisms of cytokine receptor activation. Biochem Biophys Acta. 2002;1592:215-223.
  5. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109.
  6. Bukowski R, Cella D, Gondek K, Escudier B. Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. Am J Clin Oncol. 2007;30:220-227.
  7. Negrier S, Jäger E, Porta C, et al, for the Sorafenib TARGETs Clinical Trial Group. Subgroup analysis of TARGETs: sorafenib in patients with advanced renal cell carcinoma (RCC) and prior cytokine therapy. Presentation: 31st ESMO Congress; September 29-October 3, 2006; Istanbul, Turkey.
  8. Cancer Therapy Evaluation Program—National Cancer Institute web site. Common terminology criteria for adverse events, v3.0 (CTCAE). Available at: http://ctep.cancer.gov/forms/CTCAEv3.pdf.
  9. Kastan MB, Skapek SX. Molecular biology of cancer: the cell cycle. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:91-109.
  10. Stetler-Stevenson WG, Kleiner DE Jr. Molecular biology of cancer: invasion and metastases. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:123-136.
  11. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
  12. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865–875.
  13. Linehan WM, Bates SE, Yang JC. Cancers of the Genitourinary System: cancer of the kidney. In: DeVita VT Jr, Helman S, Rosenberg, SA, eds, Cancer: Principles & Practice of Oncology. 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2005:1139–1168.

Next: Clinical Experience Presentations
 
Term
Explanation for term.